title: Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP.
abstract: Appropriate restoration of blood flow via angiogenesis is critical for the recovery from ischemic stroke. Previously, we reported that treatment with dl-3n-butylphthalide (NBP) increases the number of local potent cerebral microvessels. However, the underlying mechanism remained unclear. The present study was conducted to test whether NBP enhances post-ischemic cerebral angiogenesis via vascular endothelial growth factor (VEGF) and hypoxia induced factor-1 alpha (HIF-1 alpha). Stroke-prone renovascular hypertensive rats (RHRSP) were used to create middle cerebral artery occlusion (MCAO) model. NBP was given 80 mg/kg per d for 10 consecutive days, starting 12, 24, 48 and 72 h respectively after MCAO. Neurological function was assessed daily and infarct volume as well as the expressions of CD31, VEGF, HIF-1 alpha and bFGF was detected 13 days after MCAO. The administration of NBP starting within 24 h after MCAO enhanced recovery of neurobehavioral function, reduced infarct volume, increased the quantity of CD31 positive vessels, and up-regulated expressions of VEGF and HIF-1 alpha. These findings suggest that treatment with NBP within 24 h post-ischemic stroke rescues brain tissue by enhancing angiogenesis associated with up-regulation of VEGF and HIF-1 alpha expressions.
authors.affiliation: The Department of Neurology, First Affiliated Hospital of Sun Yat-sen University, Guang Zhou 510080, Guang Dong Province, PR China.
authors.forename: Song-Jie
authors.initials: SJ
authors.lastname: Liao
authors.forename: Jian-Wen
authors.initials: JW
authors.lastname: Lin
authors.forename: Zhong
authors.initials: Z
authors.lastname: Pei
authors.forename: Chun-Ling
authors.initials: CL
authors.lastname: Liu
authors.forename: Jin-Sheng
authors.initials: JS
authors.lastname: Zeng
authors.forename: Ru-Xun
authors.initials: RX
authors.lastname: Huang
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use; D000818:Animals; D001572:Benzofurans / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000098:blood supply* / Q000378:metabolism; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D007150:Immunohistochemistry; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D051381:Rats; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D043925:Angiogenesis Inducing Agents; D001572:Benzofurans; D004365:Drugs, Chinese Herbal; C497444:Hif1a protein, rat; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; C027125:3-n-butylphthalide